Company news
Viatris Inc. (NASDAQ:VTRS) news
Viatris Inc. news releases on 6ix. Latest, Oct 5, 2026: Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
Press releases & updates
Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
October 4, 2026
Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
October 5, 2026
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
September 29, 2026
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
September 28, 2026
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
September 16, 2026
Viatris Reports Second-Quarter 2026 Financial Results
August 6, 2026
Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
July 29, 2026
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
July 1, 2026
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
June 29, 2026
Viatris Recognized as One of the 2026 Best Workplaces™ in Canada
June 16, 2026
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
May 18, 2026
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference
May 7, 2026
Viatris Announces Chief Financial Officer Transition
May 4, 2026
Chlorpheniramine Maleate - Global Market Insights, Competitive Landscape & Industry Forecast to 2033 Featuring Viatris, Alkem Labs, Merck & Co., Johnson & Johnson, Capellon Pharma and More
May 1, 2026
Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting
May 1, 2026
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026
April 13, 2026
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
April 10, 2026
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
March 22, 2026
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
March 18, 2026
GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications
March 11, 2026
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
February 25, 2026
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
February 25, 2026
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
February 24, 2026
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
February 17, 2026
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
February 3, 2026
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
February 3, 2026
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
January 19, 2026
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
January 8, 2026
Viatris Provides Pipeline Update on Four Regulatory Milestones
December 17, 2025
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 16, 2025
Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back
December 15, 2025
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
December 5, 2025
Viatris to Participate in Upcoming Investor Conferences
November 23, 2025
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 20, 2025
Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025
November 12, 2025
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 10, 2025
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
November 5, 2025
Policy Engagement to Break Down Barriers to Access and Build Resilient Health Systems at Viatris
November 4, 2025
Viatris Announces Quarterly Dividend
November 3, 2025
Collaborating to Address Antimicrobial Resistance at Viatris
October 28, 2025
Locus Biosciences Enters Research Collaboration to Develop Precision Antibacterial Therapies for Ophthalmic Infections
October 28, 2025
How Viatris is Fighting Infectious Disease
October 21, 2025
How Viatris Prevents and Manages NCDs
October 15, 2025
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
October 14, 2025
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row
October 7, 2025
Viatris’ Work To Advance Access and Public Health
October 7, 2025
Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025
September 30, 2025
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer
August 18, 2025
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.
August 10, 2025
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance
August 6, 2025